Ocular penetration of moxifloxacin 0.5% and gatifloxacin 0.3% ophthalmic solutions into the aqueous humor following topical administration prior to routine cataract surgery

Current Medical Research and Opinion

Volumn 21, Issue 1, 2005, Pages 93-94

  Kim, Dianne H ^a   Stark, Walter J ^a   O'Brien, Terrence P ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

Antibiotics, ophthalmic; Cataract surgery; Fluoroquinolone; Gatifloxacin; Moxifloxacin

Indexed keywords

CYCLOPENTOLATE; GATIFLOXACIN; LIDOCAINE; MOXIFLOXACIN; PHENYLEPHRINE; PROXYMETACAINE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TROPICAMIDE;

AQUEOUS HUMOR; ARTICLE; CATARACT; CATARACT EXTRACTION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG PENETRATION; EYE INFECTION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MASS SPECTROMETRY; OUTCOMES RESEARCH; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; TANDEM MASS SPECTROMETRY; UNITED STATES;

ADMINISTRATION, TOPICAL; ANTI-INFECTIVE AGENTS; AQUEOUS HUMOR; AZA COMPOUNDS; CATARACT EXTRACTION; DOUBLE-BLIND METHOD; FLUOROQUINOLONES; HUMANS; OPHTHALMIC SOLUTIONS; PROSPECTIVE STUDIES; QUINOLINES;

EID: 14744275481     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079904X20240     Document Type: Article

References (8)

1. McDonnell PJ. Endophthalmitis risk factors: clear corneal incision? Presented at the American Academy of Ophthalmology, New Orleans. LA, October 25, 2004. Available from: http://www.aao. org/aao/annual_meeting/program [last accessed: 2 December 2004]
2. Alexandrakis G, Alfonso EC, Miller D. Shifting trends in bacterial keratitis in South Florida and emerging resistance to fluoroquinolones. Ophthalmology 2000;107:1497-502
3. Mah FS. Which topical fluoroquinolone to use? Presented at the American Academy of Ophthalmology, New Orleans. LA, October 25, 2004. Available from: http://www.aao.org/aao/annual_meeting/program [last accessed: 2 December 2004]
4. Neu HC. Microbiologic aspects of fluoroquinolones. Am J Ophthalmol. 1991;112:15S-24S.
5. Katz HR, Masket S, Lane SS, et al. Absorption of topical moxifloxacin ophthalmic solution into human aqueous humor. Cornea [in press]
6. Schentag JJ, Gilliland KK, Paladino JA. What have we learned from pharmacokinetic and pharmacodynamic theories? Clin Infect Dis 2001;32(Suppl. 1):S39-46
7. Metzler K, Hansen GM, Hedlin P, Harding E, Drlica K, Blondeau JM. Comparison of minimal inhibitory and mutant prevention drug concentrations of 4 fluoroquinolones against clinical isolates of methicillin-susceptible and -resistant Staphylococcus aureus. Int J Antimicrob Agents 2004;24:161-7
8. Mather R, Karenchak LM, Romanowski EG, Kowalski RP. Fourth generation fluoroquinolones: New weapons in the arsenal of ophthalmic antibiotics. Am J Ophthalmol. 2002;133:463-6